


Remarks/Arguments

Claims 2-12, 14 and 18-133 are pending. Applicants respectfully request reconsideration and allowance of the pending claims in light of the following remarks.

Contrary to what is stated in the Office Action, all of the pending claims are directed to methods. None of the pending claims are directed to pharmaceutical compositions.

The Office Action requires an election of species and reserves its determination of the restricted invention until conducting an additional examination of the elected subject matter in view of the scope of the pending claims. In the context of the pending method claims, applicants understand this requirement to mean that they are electing a single compound for use in the recited methods as a vehicle for the Examiner to focus the examination of the pending claims.

In response to this election requirement, applicants elect the compound of Example 332 as follows:



1-[6-(1-methyl-azetidin-3-ylmethoxy)-pyridin-2-yl]-3-(2-pyridin-4-yl-thiazol-4-yl)-urea

With respect to the formula VI of claim 14, this compound has the following substituents:

R¹⁵ – optionally substituted heterocycl-yl-C₁-C₄-alkoxy (specifically azetidin-3-ylmethoxy) with the substituent comprising a methyl group;

R¹⁶ – H


R^{17} – unsubstituted 6-membered nitrogen-containing heterocyclyl (specifically pyridin-4-yl)

With respect to formula I of claim 18, this compound has the following substituents:

$A^1 - C$; $A^2 - N$; $A^3 - C$; $A^4 - S$; $A^5 - CH$;

q is 0;

R^2 – substituted or unsubstituted 5-6 membered heterocyclyl (specifically an unsubstituted 6-membered nitrogen containing heterocyclyl – unsubstituted pyridine-4-yl), substituted on A^1 ;

Y is  (the last of the five formulae for Y where R^6 is H and r is 0);

X and Z combine to form a 6-membered nitrogen-containing heterocyclyl (pyridinyl) substituted with one substituent selected from R^1 ; and

R^1 is OR^3 , where R^3 is an optionally substituted heterocyclylalkyl (specifically an optionally substituted azetidin-3-ylmethyl, with the substituent comprising a methyl group).

In accordance with the Office Action, further action by the Examiner is now anticipated in the form of a restriction requirement, to which applicants reserve the right to respond.

Reconsideration and formal allowance of the pending claims thus are respectfully requested.

Respectfully submitted,

By: 

Joseph M. Skerpon
Registration No. 29,864

Dated: November 2, 2005

BANNER & WITCOFF, LTD.
1001 G Street, N.W. - Eleventh Floor
Washington, D.C. 20001-4597
(202) 824-3000
JMS/bao